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High-risk human papillomaviruses (HPVs) are etiologically implicated in human cervical cancer. Two viral genes, E6 and E7,
are commonly found expressed in these cancer cells. We have previously shown that mice transgenic for the HPV-16 E6 gene
or E7 gene, in which the E6 or E7 was expressed in the basal layer of epithelia, developed skin tumors. The spectrum of
tumors derived from E6 and E7 mice differed, however; although most tumors derived from the E7-transgenic mice were
benign, the majority of the tumors from the E6-transgenic mice were malignant. These findings led us to hypothesize that E6
and E7 play different roles in carcinogenesis. To assess at what stages in carcinogenesis E6 and E7 act, we treated the skin
of K14E6- and K14E7-transgenic mice with chemical carcinogens known to contribute to distinct stages in carcinogenesis.
Both E6 and E7 were found to synergize with chemical carcinogens in causing tumor formation. E6 was found to act weakly
at the promotion stage of carcinogenesis in the formation of benign tumors but strongly at the progression stage which
involves the malignant conversion of benign tumors. In contrast, E7 primarily affected the promotion stage of carcinogenesis.
These results provide direct evidence that E6 and E7 contribute differently to carcinogenesis; E7 promotes the formation of
benign tumors, and E6 acts primarily to accelerate progression of these benign tumors to the malignant stage. Consistent
with this model, we found E6 and E7 to cooperate in inducing tumor formation in mice expressing both oncogenes. © 2000
Academic Press
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Human papillomaviruses (HPVs) are small DNA tumor
viruses that cause benign tumors or warts in human skin.
A subset of anogenital HPVs, the high-risk HPVs, are
also associated with malignant tumors, including the
majority of cervical cancers (zur Hausen, 1996). HPV-
associated cervical carcinogenesis is a multistep pro-
cess, in which infected cells develop into squamous
intraepithelial lesions (SIL) (Wright et al., 1994). In these
lesions, cells become atypical and mitotically active and
lose their ability to terminally differentiate. In low-grade
SIL stage, these abnormal cells are limited to the lower
portion of the epithelia. Low-grade SIL associated with
high-risk HPVs can progress to high-grade SIL, in which
abnormal cells are evident throughout the entire thick-
ness of the epithelia, and eventually to cervical carci-
noma. During this multistep process, high-risk HPV ge-
nomes commonly integrate into cellular chromosomes
(Baker et al., 1987; Choo et al., 1987; Cooper et al., 1992;
aniel et al., 1997), and two early genes, E6 and E7,
ecome selectively overexpressed. E6 and E7 genes can
ransform cells in culture, and their transforming ability is
ue, at least in part, to their ability to interact with cellular
umor suppressor proteins. E6 binds the tumor suppres-
or p53 through its interaction with another cellular pro-
1 To whom reprint requests should be addressed. Fax: (608) 262-
824. E-mail: Lambert@oncology.wisc.edu.
141ein, E6 associated protein (E6-AP), leading to the deg-
adation of p53 via the ubiquitin-mediated protein deg-
adation pathway (Huibregtse et al., 1991; Scheffner et
l., 1993, 1990; Werness et al., 1990). The inactivation of
53 appears to be required but may not be sufficient for
6 to transform most cell types, because the loss of p53
unction does not transform or immortalize cells as effi-
iently as does E6 (Dalal et al., 1996; Nakagawa et al.,
995). Recently, several other cellular factors have been
ound to associate with E6 protein; these cellular pro-
eins include E6 binding protein (Chen et al., 1995), pax-
llin (Tong and Howley, 1997), the human homolog of
rosophila discs large tumor suppressor protein (Kiyono
t al., 1997; Lee et al., 1997), and the newly identified
protein E6 target protein 1, a putative GAP protein (Gao et
al., 1999). E6’s association with these proteins may con-
tribute to E6’s transforming ability. E7 binds and de-
grades the retinoblastoma tumor susceptibility gene
product (pRb) (Dyson et al., 1989; Jones et al., 1997). E7
also binds the other members of the pRb “pocket” protein
family: p107 and p130 (Dyson et al., 1992). The binding of
E7 to the pocket proteins leads to deregulation of the G1
to S transition in the cell cycle. Mutations in the con-
served region (CR) 2 domain of E7 that mediates its
binding to pRb abrogate E7’s ability to transform cells,
indicating the likely importance of pRb’s inactivation in
E7’s transforming activity (Watanabe et al., 1990). Re-
cently, E7 was also demonstrated to bind to the cyclin/
CDk inhibitor p21 (Jones et al., 1997) and p27 (Zerfass-
Thome et al., 1996) and to associate directly with cyclins
0042-6822/00 $35.00
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142 SONG ET AL.A and E, or to increase the expression of these cyclins,
leading to deregulation of the cell cycle (Dyson et al.,
1992; McIntyre et al., 1996; Zerfass et al., 1995). Taken
together, it appears that E7 primarily associates with cell
cycle-regulating proteins that control cell cycle progres-
sion at physiological conditions, whereas E6 primarily
associates with proteins important for genome stability
or associated with signal transduction pathways that
involve cell–cell interactions and contribute to the main-
tenance of cellular morphology.
The oncogenic activities of E6 and E7 have been
studied in vivo through the generation and characteriza-
ion of E6- and E7-transgenic mice. When expressed in
arious tissues by different transcriptional promoters, E6
nd E7 together can induce various types of tumors,
epending on the type of tissue expressing these two
enes (Arbeit et al., 1993; Greenhalgh et al., 1994; Griep
t al., 1993). To define the roles of E6 and E7 individually
n carcinogenesis, workers at our laboratory generated
6 (K14E6)- or E7 (K14E7)-transgenic mice in which each
ene was directed in its expression to basal epithelial
ells of the epidermis using the human keratin 14 (hK14)
ranscriptional promoter. E6 and E7 each could induce
kin hyperplasia and skin tumors (Herber et al., 1996).
owever, the spectrum of tumors derived from E6- and
7-transgenic mice appeared to differed. E6 primarily
nduced malignant skin tumors, whereas E7 primarily
nduced benign skin tumors. Based on these observa-
ions, we hypothesized that E6 and E7 play distinct roles
n HPV carcinogenesis. To determine how E6 and E7
ontribute to HPV-induced carcinogenesis, we studied
6 and E7 in the context of a model for multistage skin
arcinogenesis, in which the carcinogenic process is
ivided into three stages: initiation, promotion, and pro-
ression (see review in Boutwell, 1989). Chemical car-
inogens and oncogenes preferentially affect specific
tages. For instance, the ras mutation is considered an
nitiating event in carcinogenesis (Brown et al., 1986). To
assess the stages in the carcinogenesis in which E6 and
E7 act, skin tumor induction experiments were carried
T
Histological Characterization of Skin Tumors
Transgene
No. of tumors
examined
No. of benign
tumors
K14E6a 24 6
K14E7b 9 8
a Data taken from ref. 31; the tumors were scored between 6 and 15
b Four were papillomas, three were benign sebaceous adenomas, one
malignant transformation. The tumors were scored between 6 and 15
c The percentage of malignancy between the two groups was signifout on the K14E6 and K14E7 mice with chemical carcin-
ogens known to act at distinct stages in carcinogenesis.E6 was found to increase malignant progression of
chemically induced skin papillomas, whereas E7 only
promoted the formation of papillomas. This result sup-
ports our hypothesis that E6 and E7 act differently at the
multiple stages in carcinogenesis. Consistent with these
findings, E6 and E7 were found to act cooperatively to
induce the development of cancer.
RESULTS
Skin tumors derived from K14E6- and K14E7-
transgenic mice differ in grade of malignancy
We reported earlier that E6 and E7 induce skin tumors
in K14E6- and K14E7-transgenic mice, respectively, when
these genes were expressed individually in the undiffer-
entiated epithelial cells of the epidermis (Herber et al.,
1996; Song et al., 1999). E6 and E7 induced different
ypes of tumors. Grossly, the tumors arising in the K14E6
ice were mostly open and invasive, indicative of ma-
ignancy, and arose with an average age of onset of 12
onths; whereas tumors arising in K14E7 mice were
ostly self-contained and indicative of benign papillo-
as and arose with an average age of onset of 10.4
onths. Histopathological analysis was performed to
ompare the degree of malignancy of tumors from both
roups of mice (Table 1). The skin tumors from K14E7
ice were primarily benign papillomas and sebaceous
pitheliomas, and only one of the nine skin tumors ex-
mined had any signs of malignancy; it was a papilloma
ith early malignant transformation, which was catego-
ized as a grade I epidermoid carcinomas in Table 1. In
ontrast, the majority of the tumors from K14E6 mice
ere malignant epidermoid carcinomas (18 of 24, or 75%)
P , 0.005). Of the 18 malignant tumors arising in the
K14E6 mice, 5 were grade I, 11 were grade II, and 2 were
grade III epidermoid carcinomas. Thus the range in
grade of malignancy of tumors derived from K14E6- and
K17-transgenic mice also differed significantly. From
these results we conclude that E6 primarily induces
ed from K14E6 and K14E7 Transgenic Mice
Carcinoma grade
MalignancycI II III
5 11 2 75%
1 0 0 11%
s of age.
keratoacanthoma, and one was a papilloma with foci of probable early
of age.
different (P , 0.01).ABLE 1
Deriv
month
was amalignant tumors, whereas E7 primarily induces benign
tumors.
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143ROLES OF HPV-16 E6 AND E7 GENES IN CARCINOGENESISE7 increases the yield of chemically induced
papillomas and primarily enhances promotion
in carcinogenesis
Carcinogenesis is divided into three stages: initiation,
promotion, and progression (Boutwell, 1989; Drinkwater,
1990). At appropriate doses, the mutagen 7,12-dimethyl-
benz[a]anthracene (DMBA) can only initiate. In contrast,
12-O-tetradecanoyl-phorbol-13-acetate (TPA) can only
promote (Ordman et al., 1985). To examine the role of E7
n carcinogenesis, we tested how E7 affected carcino-
enesis induced by chemical carcinogens. We treated
roups of K14E7-transgenic mice with a single dose of
nitiator DMBA (0.01 or 0.03 mmol) to the skin on the
back, followed by twice-weekly treatments with the pro-
moting agent TPA for 20 weeks. Groups of nontransgenic
mice were treated with these two agents on the same
schedules. Papillomas were counted every other week.
A significantly greater number of papillomas (P , 0.001)
were observed on the K14E7-transgenic mice in both
treatment groups compared with that in the nontrans-
genic mouse groups, and these tumors developed ear-
lier in K14E7-transgenic mice (Figs. 1A and 1B). A high
percentage of the DMBA- and TPA-treated K14E7 mice,
but no DMBA- or TPA-treated nontransgenic mice, devel-
oped benign sebaceous epitheliomas during the 20-
week treatment period. This is a tumor type that can
arise spontaneously in older K14E7 mice (Herber, et al.,
1996); their more rapid development in the treated mice
indicates that E7 can synergize with DMBA and/or TPA to
induce this benign tumor type as well. Together, these
results indicate that E7 acts in the early stages of carci-
nogenesis, leading to papilloma formation.
To determine whether E7 also affects the later, malig-
nant progression stage of carcinogenesis, the papillo-
mas that had formed on the K14E7 and nontransgenic
mice induced by DMBA and TPA were monitored for
malignant progression after termination of the TPA treat-
ment. Due to the large number of benign sebaceous
epitheliomas and large papillomas on the K14E7 mice,
these mice had to be sacrificed for humane reasons by
14 weeks into this monitoring period. Papillomas that
became open, ulcerated, and flattened with a wide base
were clinically diagnosed to have progressed to a ma-
lignant state. Mice with these tumors were sacrificed,
and tumors were collected for histopathology. Papillo-
mas from both nontransgenic mice and K14E7-trans-
genic mice were able to progress to carcinomas. The
frequency of malignant progression was low in both
groups of mice (Table 2). At 14 weeks after termination of
skin treatment with chemical carcinogens, the percent-
age of papillomas that progressed to malignant carcino-
mas in the nontransgenic and K14E7-transgenic mice
was not statistically different (P 5 0.45). Thus E7 doesot play a role in progression.
Papilloma formation requires the action of two types of
i
iarcinogens: an initiator and a promoter. To determine at
hich of the early stages E7 might act, we treated groups
f nontransgenic and K14E7 mice either with a single
pplication of the initiator DMBA or with twice-weekly
pplications of the promoter TPA for 20 weeks. As ex-
ected, no tumors developed in the groups of nontrans-
enic mice treated with either DMBA only or TPA only,
hich is consistent with the requirement of both initiator
nd promoter for papilloma formation. Likewise, the
14E7 mice treated with TPA only did not develop any
kin tumors. However, the group of K14E7 mice treated
ith DMBA only developed papillomas, with a multiplicity
f 0.8 per mouse at the end of 20 weeks (Fig. 1C; P 5
.04). That an initiator could synergize with E7 to induce
apillomas indicates that E7 acts as a promoter in car-
inogenesis. The inability of E7 to synergize with TPA to
FIG. 1. Tumor induction with chemical carcinogens in K14E7-trans-
genic mice. Groups of 20–30 K14E7-transgenic mice (l) and nontrans-
genic control mice (f) were treated with a single dose of DMBA, 0.01
mmol (A) or 0.03 mmol (B) on day 1, followed by TPA treatment (2.5
mg/treatment) twice a week for 20 weeks. Papillomas were counted
every 2 weeks during TPA treatment. To examine the effect of E7 on
promotion in carcinogenesis, groups of mice were treated with a single
dose of DMBA (0.3 mmol) and monitored for tumor formation for 20
eeks (C). Statistical analysis was performed for each treatment (P ,
.01 for panel A and B, P 5 0.04 for panel C).nduce tumors indicates that E7 does not act as an
nitiator.
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144 SONG ET AL.E6 weakly potentiates tumor development after
chemical carcinogenesis and primarily enhances
malignant progression
Similarly, we asked at what stages E6 acts in carcino-
genesis. We treated groups of K14E6 mice with DMBA
and TPA and monitored the development of papillomas.
K14E6-transgenic mice treated with 0.01 mmol of DMBA
produced a statistically (P , 0.01) higher number of
apillomas than did nontransgenic mice (Fig. 2A). How-
ver, the numbers of papillomas induced in the K14E6
ice treated with a higher dose of DMBA (0.03 mmol) did
not differ from that seen in nontransgenic mice (P 5 0.4)
(Fig. 2B). This result suggested that E6 might synergize
with chemical carcinogens in the induction of papillomas
but that its action is weak and therefore easily masked
when higher levels of chemical carcinogens are used.
This is in contrast to E7, which could synergize even with
high levels of chemical carcinogens to induce papilloma
formation. Sebaceous epithelioma was not commonly
seen in the K14E6 mice with or without treatment with
chemical carcinogens.
To determine at which stage, initiation or promotion,
E6 weakly acts, we treated K14E6 and nontransgenic
mice with DMBA or TPA only. No tumors developed in the
groups of K14E6 or nontransgenic mice treated with TPA
only (data not shown), indicating the E6 does not act as
an initiator. However, tumors did develop in the group of
K14E6-transgenic mice treated with DMBA only (Fig. 2C),
although the multiplicity of only 0.156 papilloma per
mouse was far less than that seen in the K14E7 mice.
This result indicates that E6 acts as a promoter in the
formation of papillomas but that its action at this stage of
carcinogenesis is weak compared with E7.
TABLE 2
Comparison of Malignant Progression in Nontransgenic versus
K14E7 Transgenic Mice
Micea
No. of
mice
No. of carcinomas/
mouse
Percentage of
papillomas
progressedb
Nontransgenic 31 0.226 2.97
K14E7 24 0.333 3.11
a The mouse groups that were monitored for progression were those
escribed in the legend to Fig. 1A [i.e., those treated with single dose
f DMBA (0.01 mmol), followed by treatment with TPA (2.5 mg), twice a
eek for 20 weeks]. Mice were monitored for an additional 14 weeks
or tumor progression. Data were obtained at 34 weeks after treatment
ith DMBA (0.01 mmol). All malignant tumors were confirmed by his-
opathology.
b Calculated based on the number of carcinomas that had developed
by week 34 as a fraction of the number of papillomas observed at the
termination of TPA treatment (week 20). The difference between the two
groups was not statistically significant (P 5 0.45).To study the function of E6 in progression of carcino-
genesis, the papillomas induced by treatment withDMBA and TPA were monitored for malignant progres-
sion for an additional 20 weeks after termination of skin
painting with the promoting agent TPA. The chemically
induced papillomas on the E6-transgenic mice converted
to a malignant state earlier than papillomas from non-
transgenic mice, and the rate of malignant conversion
was higher than the papillomas in nontransgenic mice
(Table 3). The difference in the percentage of papillomas
progressing to malignant tumors between E6-transgenic
mice and nontransgenic mice was statistically significant
(P , 0.05), indicating that E6 increases the malignant
rogression of chemically induce papillomas. The in-
rease in malignant conversion in the K14E6 mice could
lso be seen by 14 weeks after the termination of TPA
reatment, the end point used in the analysis of progres-
ion in the K14E7 mice. Thus E6 contrasts with E7 in its
bility to cause malignant progression.
FIG. 2. Tumor induction with chemical carcinogens in K14E6-trans-
genic mice. Groups of 20–30 K14E6-transgenic mice (F) and nontrans-
genic control mice (f) were treated with a single dose of DMBA, 0.01
mmol (A) or 0.03 mmol (B) on day 1, followed by TPA treatment (2.5
mg/treatment) twice a week for 20 weeks. Papillomas were counted
every 2 weeks during TPA treatment. To examine the effect of E6 on
promotion in carcinogenesis, groups of mice of each strain were
treated with a single dose of DMBA (0.3 mmol) and monitored for tumor
formation for 20 weeks (C). Statistical analysis was performed for each
treatment (P , 0.01 for panel A, P 5 0.4 for panel B, and 0.08 for panel
C).
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145ROLES OF HPV-16 E6 AND E7 GENES IN CARCINOGENESISE6 cooperates with E7 in induction of carcinogenesis
Taken together, our skin-painting experiments indicate
that E7 acts at the promotion stage and that E6 acts
primarily at the progression stage in carcinogenesis. To
further test this hypothesis, we looked at whether E6 and
E7 cooperate in carcinogenesis. A synergistic effect be-
tween these genes would be consistent with the hypoth-
esis that these two genes act at different stages in
carcinogenesis. We generated K14E6xK14E7 double-
transgenic mice by crossing our E6-transgenic mice (line
5737) and E7-transgenic mice (line 2304). By doing so,
the gene doses of E6 or E7 in these double-transgenic
mice are equivalent to that in K14E6- or K14E7-transgenic
mice, respectively. Tumor incidence in K14E6 3 K14E7
double-transgenic mice was monitored and compared
with that of K14E6- or K14E7-transgenic mice. Skin tu-
mors developed earlier in the K14E6 3 K14E7 mice, and
the tumor incidence was statistically significantly higher
(P , 0.001) than that seen in either K14E6 or K14E7 mice
(Fig. 3). The tumors that arose in these mice were a
combination of sebaceous epitheliomas (;30%) and
squamous tumors (;70%), with the vast majority of the
latter being malignant carcinomas. Both tumor types
arose earlier and with higher frequency in the doubly
transgenic mice than in the singly transgenic mice. The
sebaceous epitheliomas were seen only in the singly
transgenic K14E7 mice, not in the K14E6 mice; their
earlier onset and higher frequency in the doubly trans-
TABLE 3
Comparison of Malignant Progression in Nontransgenic versus
K14E6 Transgenic Mice
Micea
No. of
mice
No. of carcinomas/
mouse
Percentage of
papillomas
progressedb
Nontransgenic 18 0.11 (0)c 5.56 (0)
14E6 19 0.894 (0.37) 19.78 (7.78)
a The mouse groups that were monitored for progression were those
escribed in the legend to Fig. 2A [i.e., those treated with single dose
f DMBA (0.01 mmol), followed by treatment with TPA (2.5 mg), twice a
eek for 20 weeks]. Mice were monitored for an additional 20 weeks
or tumor progression. Data were obtained at 40 weeks after treatment
ith DMBA (0.01 mmol). All malignant tumors were confirmed by his-
opathology.
b Calculated based on the number of carcinomas that had developed
by week 40 as a fraction of the number of papillomas observed at the
termination of TPA treatment (week 20). The difference between the two
groups was statistically significant (P , 0.05).
c Numbers in parentheses indicate data obtained at week 34. Note
that differences in number of carcinomas per mouse in nontransgenic
controls at this time point compared with that reported in Table 2 reflect
differences in specific activity of DMBA used in these two experimental
studies, as evidenced by the 4-fold difference in frequency of papillo-
mas (compare data in Fig. 2A with that in Fig. 1A).genic mice compared with the K14E7 mice suggest that
E6 can contribute to the development of this tumor type mwhen coexpressed with E7. These results clearly indi-
cate that E6 and E7 cooperate in carcinogenesis.
H-ras mutation does not contribute to the increased
malignant progression of the chemically induced
tumors in E6-transgenic mice
Cells transformed by E6 and E7 could not form tumors
when transplanted into nude mice, but cells transformed
by these genes in combination with other oncogenes,
such as activated ras, can form tumors in animals (Crook
et al., 1988; Lambert et al., 1993; Liu et al., 1995). To test
hether E6’s ability to increase progression of chemi-
ally induced tumors is associated with increased H-ras
ctivation, we looked at the frequency of H-ras mutations
n the chemically induced tumors. Because DMBA-in-
uced mutations in H-ras are almost exclusively A 3 T
transversions at codon 61 (Quintanilla et al., 1986), we
nalyzed the mutations at this codon 61 by PCR–restrict
ragment length polymorphism (RFLP). All the mutations
hat occurred were A 3 T transversions at the second
osition of codon 61. There was no difference in the
requency of H-ras mutations at this codon between
umors from nontransgenic and K14E6-transgenic mice
Table 4). Mutations at codon 61 were detected more
requently in carcinomas than papillomas from both
roups of mice. We concluded that the increased malig-
ant progression of tumors in E6-transgenic mice was
ot associated with increases in H-ras mutations.
FIG. 3. Cooperation between E6 and E7 genes in tumorigenesis. The
K14E6 3 K14E7 double transgenics () were generated by crossing
K14E6 (line 5737, F) and K14E7 (line 2304, f) mice that had been used
in this study for analysis of spontaneous tumors and for tumor induction
assays.
TABLE 4
H-ras Mutations at Codon 61 in Tumors Induced with Carcinogens
in Nontransgenic versus K14E6-Transgenic Mice
Codon 61 Tumors from nontransgenic Tumors from K14E6 mice
AA to GAA 0/25 0/30
AA to CTA 21/25 (84%) 25/30 (83.3%)
AA to CAT 0/25 0/30Note. Values in the table the represent the number of tumors with ras
utations as a fraction of the total number of tumors examined.
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146 SONG ET AL.DISCUSSION
HPV-induced carcinogenesis is a multistep process in
hich the normal cervical epithelia initially develops
ytological changes referred to histologically as SIL
Wright et al., 1994). If the high-risk HPV infection per-
ists, the SIL can progress from low grade to high grade
nd, after a long latency period, to invasive carcinoma. In
his process, the E6 and E7 genes are expressed in the
ells and considered to contribute to this carcinogenic
rocess. In this study, we identified the stages in carci-
ogenesis at which E6 and E7 act. E7 and, to a lesser
egree, E6 were found together with the initiator DMBA
o induce formation of benign tumors. These data indi-
ate that E7 acts strongly and E6 acts weakly at the
romotion stage of carcinogenesis. E6 also contributes
o the progression stage of carcinogenesis as evidenced
y the increased percentage of papillomas that became
alignant. E7 did not affect progression. Thus E6 and E7
lay different roles in carcinogenesis; E7 strongly con-
ributes to benign tumor formation, whereas E6 strongly
ontributes to malignant transformation. Correspond-
ngly, the two genes together were found to act syner-
istically in the spontaneous induction of tumors.
he role of E7
One common property of carcinogenic promoting
gents, including TPA, is their ability to induce cellular
yperplasia (Imamoto et al., 1993; Pence and Reiners,
987). E7’s tumor-promoting activity may reflect its ability
o interact with cell cycle-regulating proteins and induce
ellular proliferation in cell culture and in animals. In the
14E7 mice, E7 induces epidermal hyperplasia (Herber
t al., 1996). The proliferation index in the basal layer of
he epithelia of these mice was increased, and cells in
he suprabasal compartment of the epidermis, where
ells normally cease to proliferate, were still able to
ynthesize DNA and divide (Gulliver et al., 1997). This
ctivity was dependent on its ability to inactivate pRb and
Rb-like proteins (Gulliver et al., 1997). Sebaceous epi-
theliomas, which can spontaneously develop in K14E7
mice, were also frequently induced by DMBA only in this
transgenic strain, indicating that E7 acts to promote two
types of benign skin tumor.
In our analysis of spontaneously arising tumors and
carcinogen-induced tumors, we concluded that E7 does
not contribute significantly to malignant progression in
carcinogenesis. The conclusion is consistent with stud-
ies that demonstrated E7 is only weakly capable of
inducing gross chromosomal alterations, such as aneu-
ploidy, that are indicative of malignancy (Reznikoff et al.,
1994; White et al., 1994). This result is also consistent
with an early finding that the inactivation of the p16/cdk/
cyclin-pRb cascade does not occur during malignant
transformation but rather during an early step in the
a
fimmortalization of cells by HPV-16 or -18 (Nakao et al.,
1997). The p16-pRb cascade is disrupted by E7.
The role of E6
In this study, we conclude that E6’s primary oncogenic
contribution to carcinogenesis is to cause tumors to
progress to the malignant state. E6 may enhance malig-
nant progression through several mechanisms. First, E6
has been demonstrated in cell culture to induce gross
chromosomal alterations that are indicative of malig-
nancy, including chromosomal translocation and aneu-
ploidy (Reznikoff et al., 1994; White et al., 1994). These
ross chromosomal changes are also common in malig-
ant cells that have lost p53 function, indicating the E6
ay induce the genomic instability through its inactiva-
ion of p53. Consistent with this argument, a reduction in
53 gene dose can accelerate malignant progression in
arcinogenesis but does not affect tumor promotion in
arcinogenesis (Kemp et al., 1993). E6’s inactivation of
53 is functionally equivalent to a reduction in p53 gene
ose. Second, E6 can inhibit cellular differentiation. In
he lens of the mice that express the E6 gene, terminal
ifferentiation was disrupted and the lens fiber cell de-
ucleation process was inhibited (Pan and Griep, 1994).
n cell culture, the E6 was found to increase the resis-
ance to calcium-induced differentiation of human kera-
inocytes through a process that requires, at least in part,
53-independent activities of E6 (Sherman et al., 1997;
Sherman and Schlegel, 1996). In addition, we have found
E6 to cause an expansion in the undifferentiated com-
partment in the epithelia of the K14E6 mice; this, too,
required p53-independent activities of E6 (Song et al.,
1999). Because one of the distinct features between
benign and malignant tumors is their differentiation prop-
erties, inhibition of cellular differentiation by E6 may
contribute to malignant progression. Third, E6 can in-
duce activation of telomerase (Klingelhutz et al., 1996),
hich can abrogate a late step in senescence of human
ammary epithelial cells (Kiyono et al., 1998). Increased
ctivity of telomerase is seen selectively in malignant
ervical carcinomas and high-grade CIN III lesions (Klin-
elhutz et al., 1996; Snijders et al., 1998). Thus E6 may
ontribute to malignant progression via several of its
iological activities. Further studies are necessary to
scertain the contribution of each of these activities of E6
o its role in carcinogenesis.
Activated ras can cooperate with E6 or E7 to cause
alignant transformation of cells (Liu et al., 1994; Phelps
t al., 1988; Storey and Banks, 1993). Cells transformed
y E6 or E7 alone usually cannot form tumors in nude
ice, but cells transformed by E6 and activated ras can
Liu et al., 1994), indicating the cells transformed by
ooperation between E6 and activated ras were more
ggressive. Also, H-ras mutation is considered a marker
or malignant progression in some skin cancers, such as
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147ROLES OF HPV-16 E6 AND E7 GENES IN CARCINOGENESISmelanoma (Ball et al., 1994). We wanted to test whether
mutation of the ras gene was contributing to the in-
creased malignant progression of the chemically in-
duced papillomas in the K14E6-transgenic mice. Consis-
tent with our earlier result that H-ras gene mutations
were not involved in the spontaneous tumor develop-
ment in the K14E6 mice (Song et al., 1999), the frequency
of H-ras mutations was similar in tumors induced by
chemical carcinogens in both the K14E6-transgenic and
their control mice, indicating that H-ras mutations were
not contributing to the increased frequency of malignant
progression in the K14E6 mice.
We found that E6 also affected the promotion stage in
carcinogenesis. This action was weak compared with
that of E7 and probably relates to E6’s ability to induce
cellular proliferation (Song et al., 1999). Correlative to its
weak promotion activity compared with that of E7, the
proliferative index of the K14E6 epidermis is significantly
less than that of the K14E7 epidermis (Song et al., 1998).
he cooperation between E6 and E7
Supporting the hypothesis that E6 and E7 play different
oles in carcinogenesis, these two genes can cooperate
n the induction of carcinogenesis. The cooperation be-
ween E6 and E7 is consistent with earlier studies dem-
nstrating that both E6 and E7 were required for efficient
ransformation of human keratinocytes (Munger et al.,
989a). It also fits with the model that E6 and E7 act at
ifferent steps in the immortalization of primary human
ammary epithelial cells; E7 acts at an early step
hrough inactivation of the p16-pRb cascades leading to
n extended life span of primary cells, and E6 acts at a
ate step through its activation of telomerase.
We speculate that cooperation between E6 and E7
lso occurs in cervical carcinogenesis induced by HPVs.
irst, both transcripts for the E6 and E7 genes are de-
ected in cervical cancer cells. Second, E6 and E7 can
omplement each other in causing unlimited growth of
ells and malignant progression. For example, E7 can
rolong the life span of cells and therefore supposedly
nduces overgrowth of cells. However, E7 can also in-
uce apoptosis (Iglesias et al., 1998; Pan and Griep,
994); thus E7-induced lesions may not change in size as
apidly as otherwise possible. E6 inhibits this apoptosis
nduced by E7 (Pan and Griep, 1995; Stoppler et al.,
998), therefore accentuating the effects of E7 on carci-
ogenesis. Moreover, by contributing to the progression
tage of carcinogenesis, E6 likely causes E7-induced
enign tumors to convert to a malignant state. Although
7 does not overtly accelerate the malignant conversion
i.e., contribute itself to progression), through its cell
roliferation property, E7 may still contribute to the con-inued growth of malignant tumors. Thus the expression
f both E6 and E7 oncogenes in human cervix likely
c
Dontributes to the formation and maintenance of malig-
ant cervical cancer.
ynergy between HPV oncogenes and chemical
arcinogens
In this study, we demonstrate that the HPV oncogenes
an synergize with chemical carcinogens to induce tu-
ors. This result provides direct evidence that environ-
ental carcinogenic factors may affect HPV-associated
arcinogenesis. Cell culture studies demonstrated that
eratinocytes transformed by HPV-18 could not form tu-
ors in nude mice but could do so after these cells were
xposed to the chemical carcinogen N-methyl-N9-nitro-
-nitrosoguanidine, indicating a synergy between high-
isk HPVs and chemical carcinogens in the malignant
ransformation of cells (Shin et al., 1994). Epidemiological
nd clinical studies have linked smoking to cervical
ancer development (Daling et al., 1992; Kalogeraki et al.,
996), and several compounds from smoking can be
etected in cervical mucus from smokers, providing di-
ect evidence that smoking may affect the cervix (Pro-
opczyk et al., 1997). Taken together, these studies sug-
est that environmental factors may play a role in cervi-
al carcinogenesis together with HPVs. We speculate
hat the long latency period for HPV-associated cervical
arcinogenesis may not be only precipitated by other
enetic changes but may also be accelerated by envi-
onmental carcinogens.
MATERIALS AND METHODS
nalysis of malignancy of the tumors derived from
6- and E7-transgenic mice
The generation of the K14E6- and K14E7-transgenic
ice, in which either HPV-16 E6 or E7 was expressed in
he basal layer of the epidermis (Herber et al., 1996; Song
t al., 1999), was described previously. Tumors that de-
eloped on the K14E6 and K17 were excised, fixed in
uffered Formalin, and paraffin embedded. Sections of
hese tumors were stained with hematoxylin and eosin.
istopathological analysis and evaluation of the degree
f the malignancy of the skin tumors were performed by
he same pathologist. Tumors were categorized as be-
ign or malignant. Malignant tumors were graded as I
hrough IV based on the degree of differentiation of
umor cells, which is represented by the extent of kera-
inization, the atypicality, and the architectural pattern of
umor cells.
reatment of mouse skin with DMBA and TPA
Six- to 8-week-old female mice were shaved on the
ack. Mice were divided into three treatment groups
20–30 mice per group) that were treated with (1) the
arcinogenic initiator DMBA and promoter TPA, (2)
MBA only, or (3) TPA only. For the DMBA plus TPA
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148 SONG ET AL.treatment groups, a dose of 0.01 or 0.03 mmol of DMBA
dissolved in 0.1 ml of acetone was applied to the back
skin. Two weeks after the initial treatment with DMBA,
treatment with TPA began. TPA was also dissolved in
acetone; 0.1 ml of TPA solution containing 2.5 mg of TPA
was applied to the backs of mice twice a week for 20
weeks. For the DMBA-only treatment groups, mice were
treated similarly as described above but with a single
higher dose of DMBA (0.3 mmol) that was not followed by
PA treatment. For the TPA-only treatment groups, mice
ere not treated with DMBA but were treated with TPA at
dose of 2.5 mg/treatment twice a week for 20 weeks. All
ice were examined every 2 weeks to monitor the de-
elopment of papillomas.
onitoring malignant progression of chemically
nduced papillomas in mice
Groups of mice treated with both DMBA and TPA were
ept after the termination of TPA treatment. Papillomas
ere monitored for their progression to the malignant
tate. Papillomas that became flat, open, and invasive
ere clinically diagnosed as malignant. These clinically
iagnosed tumors were later confirmed to be malignant
y histopathology. Mice with open lesions larger than 0.5
m in diameter were sacrificed for humane reasons.
umor samples were collected, parts of the tumors were
rozen for genomic DNA preparation, and the remaining
umor tissue was fixed in buffered Formalin and pro-
essed for histopathological analysis.
nalysis of H-ras mutations with PCR and RFLP
H-ras mutations in the chemically induced skin tumors
ere analyzed by PCR and RFLP. Activated H-ras muta-
tions induced by DMBA commonly are A 3 T transver-
ion mutations at the second position of codon 61 in
-ras gene (Chakravarti et al., 1995). These mutations
reate new restriction sites. To determine the frequency
nd spectrum of H-ras mutations in the tumors induced
y DMBA and TPA, three possible nucleotide changes,
AA to GAA, CAA to CTA, and CAA to CAT, were ana-
yzed by PCR and RFLP. DNA fragments encompassing
odon 61 (CAA) were amplified via PCR from tumor-
erived DNA using a pair of primers. The primers were
TCCTACCGGAAACAGGTGGTC and 59-GCTAGCCAT-
GGTGGCTCACC. The PCR product was digested with
estriction enzymes XbaI, BsmpHI, or TagI to detect CAA
o CTA, CAA to CAT, or CAA to GAA mutations. PCR
roducts digested with these enzymes were run on 3%
etaphor agarose gels and examined visually by
thidium bromide staining.
tatistical analysis of tumor data
The statistical significance of the difference in the
ercentage of malignant tumors derived spontaneously
rom K14E6- and K14E7-transgenic mice and in the fre-uency of the chemically induced papillomas that pro-
ressed to malignant tumors between K14E6 mice and
heir control or K14E7 mice and their control were ana-
yzed using the x2 test. For tumor induction assays, the
verage multiplicity of tumors per mouse for different
xperimental groups at a given time point were analyzed
or statistical significance using the Student’s t test.
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